ESTABLISHMENT OF SORAFENIB-RESISTANT MOUSE RENAL CELL CARCINOMA RENCA CELLS AND CHARACTERIZATION OF THEIR ACQUIRED RESISTANT MECHANISM

被引：0
|
作者：
Kusuda, Yuji
Miyake, Hideaki
Sakai, Iori
Fujisawa, Masato
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
299
引用
收藏
页码：E121 / E121
页数：1
相关论文
共 50 条
  • [21] Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells
    Florian P. Reiter
    Gerald Denk
    Andreas Ziesch
    Andrea Ofner
    Ralf Wimmer
    Simon Hohenester
    Tobias S. Schiergens
    Matilde Spampatti
    Liangtao Ye
    Timo Itzel
    Stefan Munker
    Andreas Teufel
    Alexander L. Gerbes
    Julia Mayerle
    Enrico N. De Toni
    Cellular Oncology, 2019, 42 : 705 - 715
  • [22] Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells
    Cho, Sua
    Kim, Wonjin
    Yoo, Dayoung
    Han, Yeonju
    Hwang, Hyemin
    Kim, Seunghwan
    Kim, Jimin
    Park, Sanghee
    Park, Yusun
    Jo, Hanhee
    Pyun, Jae-chul
    Lee, Misu
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [23] Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells
    Reiter, Florian P.
    Denk, Gerald
    Ziesch, Andreas
    Ofner, Andrea
    Wimmer, Ralf
    Hohenester, Simon
    Schiergens, Tobias S.
    Spampatti, Matilde
    Ye, Liangtao
    Itzel, Timo
    Munker, Stefan
    Teufel, Andreas
    Gerbes, Alexander L.
    Mayerle, Julia
    De Toni, Enrico N.
    CELLULAR ONCOLOGY, 2019, 42 (05) : 705 - 715
  • [24] Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells
    Sua Cho
    Wonjin Kim
    Dayoung Yoo
    Yeonju Han
    Hyemin Hwang
    Seunghwan Kim
    Jimin Kim
    Sanghee Park
    Yusun Park
    HanHee Jo
    Jae-chul Pyun
    Misu Lee
    Scientific Reports, 14
  • [25] AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
    Zhou, Wei
    Lou, Weiyang
    Chen, Junru
    Ding, Bisha
    Chen, Binjie
    Xie, Haiyang
    Zhou, Lin
    Zheng, Shusen
    Jiang, Donghai
    ONCOTARGETS AND THERAPY, 2021, 14 : 1049 - 1059
  • [26] Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma
    Wang, Zhengshi
    Dai, Jiaqi
    Yan, Jie
    Zhang, Yun
    Yin, Zhiqiang
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (07) : 4770 - 4778
  • [27] Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: Characterization of sorafenib-resistant cells derived from a cutaneous metastasis
    Karashima, Takashi
    Fukuhara, Hideo
    Tamura, Kenji
    Ashida, Shingo
    Kamada, Masayuki
    Inoue, Keiji
    Taguchi, Takahiro
    Kuroda, Naoto
    Shuin, Taro
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (09) : 923 - 930
  • [28] Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
    Shrestha, Ritu
    Bridle, Kim R.
    Cao, Lu
    Crawford, Darrell H. G.
    Jayachandran, Aparna
    CURRENT ONCOLOGY, 2021, 28 (03) : 2150 - 2172
  • [29] A novel strategy for sorafenib-resistant hepatocellular carcinoma: autotaxin Inhibition by PF-8380
    Kwak, Bong Jun
    Park, Jung Hyun
    Kim, Ok-Hee
    Lee, Dosang
    Hong, Tae Ho
    Lee, Sang Chul
    Kim, Kee-Hwan
    Choi, Ho Joong
    Kim, Say-June
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (03)
  • [30] Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis
    Huang, Danping
    Yuan, Weiqu
    Li, Hanmin
    Li, Shaodong
    Chen, Zuanguang
    Yang, Hongzhi
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (03) : 1850 - 1858
12345